First Health Pharmaceuticals is going to participate in the 17th European AIDS Conference which will be held in Basel, Switzerland, November 6-9, 2019.
The European AIDS Conference is a biennial conference which aims to bring together scientists from all over Europe to share the latest research on clinical aspects of HIV. With the landscape of HIV and AIDS continually evolving, the 17th European AIDS Conference, drawing on the best and latest science, will be at the forefront of helping translate these developments into daily clinical practice. This year’s conference presentations will focus on simplifying antiretroviral treatment and new European treatment guidelines, PrEP use in Europe, HIV cure research, HIV drug resistance, sexually transmitted infections and HIV biology.
First Health Pharmaceuticals HIV research strategy
In its continuous efforts to find a cure for HIV, First Health Pharmaceuticals has set its priorities in the development of cutting-edge HIV cure strategies based on RNA technology by developing the first ever generation of Translation Inhibitor antiretroviral compounds. The DDX3 RNA helicase Translation Inhibitors offer unique possibilities uncommon to traditional HIV antivirals, such as significantly reduced resistance development, improved delivery in the body, low toxicity and the possibility of successful co-application in wake-up strategies of dormant reservoir cells.
Established in 1991, the European AIDS Clinical Society (EACS) is a not-for-profit scientific society of European professionals involved in the field of HIV/AIDS.